

**Table S1.** Platelet activation and function tests

<b>Assay</b>	<b>No. of proposed cut-offs</b>	<b>Specialities</b>	<b>No. of References</b>
Flow Cytometry	3	Cardiology, Stroke Medicine/Vascular	3 <sup>1-3</sup>
Ivy Bleeding Time	1	Cardiology	1 <sup>4</sup>
LTA/Optical Aggregrometry	19	Vascular, Cardiology, General Medicine/Surgery, Stroke Medicine, Diabetes/Endocrine, Healthy, Paediatrics	17 <sup>5-21</sup>
Multiplate ASPI Test	4	Cardiology, Stroke Medicine, Rheumatology, Nephrology	4 <sup>22-25</sup>
Multiplate TRAP Test	1	Rheumatology	1 <sup>24</sup>
PFA-100 Collagen/ADP Cartridges	12	Cardiology, Stroke Medicine, General Medicine/Surgery, Vascular Surgery, Paediatric Cardiology	16 <sup>4, 8, 26-39</sup>
PFA-100 Collagen/Epinephrine Cartridges	33	Cardiology, Stroke Medicine, Vascular Surgery, Diabetes/Endocrinology, General Medicine/Surgery, Healthy, Nephrology, Paediatric Cardiology, General Paediatrics	48 <sup>1-6, 8, 9, 18, 26-37, 40-60</sup>
Platelet Count Drop	1	Healthy	1 <sup>13</sup>
Serum Thromboxane B2	2	Cardiology, General Medicine/Surgery, Healthy	3 <sup>8, 61, 62</sup>
Thromboelastography	3	Healthy, Stroke Medicine, Cardiology	4 <sup>13, 63-65</sup>
Urinary 11-Dehydrothromboxane B2	6	Cardiology, Diabetes/Endocrinology, Healthy, Paediatrics, Stroke Medicine, High-risk obstetrics	8 <sup>13, 14, 18, 66-70</sup>
VerifyNow Aspirin Test	2	Cardiology, Healthy, Stroke Medicine, Diabetes/Endocrine, Nephrology	17 <sup>6, 9, 10, 13, 71-83</sup>
Whole Blood Aggregrometry	1	Cardiology	2 <sup>6, 45</sup>

**References to Table S1**

1. Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G, et al. France: Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. *Thrombosis Research*. 2002;107:45-9.

2. Assadian A, Lax J, Meixner-Loicht U, Hagmüller GW, Bayer PM, Hübl W. Aspirin resistance among long-term aspirin users after carotid endarterectomy and controls: flow cytometric measurement of aspirin-induced platelet inhibition. *Journal Of Vascular Surgery*. 2007;45(6):1142-7.
3. Hübl W, Assadian A, Lax J, Meixner U, Fang IF, Hagmüller G, et al. Regular Article: Assessing aspirin-induced attenuation of platelet reactivity by flow cytometry. *Thrombosis Research*. 2007;121:135-43.
4. Chakroun T, Gerotziapas G, Robert F, Lecrubier C, Samama MM, Hatmi M, et al. In vitro aspirin resistance detected by PFA-100TM closure time: pivotal role of plasma von Willebrand factor. *British Journal of Haematology*. 2004;124(1):80.
5. Linnemann B, Prochnow S, Mani H, Schwonberg J, Lindhoff-Last E, Linnemann B, et al. Variability of non-response to aspirin in patients with peripheral arterial occlusive disease during long-term follow-up. *Annals of hematology*. 2009;88(10):979.
6. Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. *European Heart Journal*. 2007;28(14):1702-8.
7. Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. *The American Journal Of Cardiology*. 2005;95(8):973-5.
8. Renda G, Zurro M, Malatesta G, Ruggieri B, De Caterina R. Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance. *Haematologica*. 2010;95(12):2095.
9. Harrison P, Segal H, Silver L, Syed A, Cuthbertson FC, Rothwell PM. Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests. *Platelets*. 2008;19(2):119-24.
10. Nielsen HL, Kristensen SD, Thygesen SS, Mortensen J, Pedersen SB, Grove EL, et al. Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry. *Thrombosis Research*. 2008;123(2):267-73.
11. Feher G, Koltai K, Kesmarky G, Toth K. Hemorheological background of acetylsalicylic acid resistance. *Clinical Hemorheology & Microcirculation*. 2008;38(3):143-52.
12. Albert SG, Hasnain BI, Ritter DG, Joist JH, Mooradian AD. Aspirin sensitivity of platelet aggregation in diabetes mellitus. *Diabetes Res Clin Pract*. 2005;70(2):195-9.
13. Blais N, Pharand C, Lordkipanidzé M, Sia YK, Merhi Y, Diodati JG. Response to aspirin in healthy individuals - Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count

- drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B2. *Thrombosis and Haemostasis*. 2009;102(8):404-11.
14. Yee DL, Dinu BR, Sun CW, Edwards RM, Justino H, Teruya J, et al. Low prevalence and assay discordance of "aspirin resistance" in children. *Pediatric Blood & Cancer*. 2008;51(1):86-92.
  15. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. Clinical study: antiplatelet therapy: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. *Journal of the American College of Cardiology*. 2003;41:961-5.
  16. Berrouschot J, Schwetlick B, von Twickel G, Fischer C, Uhlemann H, Siegemund T, et al. Aspirin resistance in secondary stroke prevention. *Acta Neurologica Scandinavica*. 2006;113(1):31-5.
  17. Guthikonda S, Mangalpally K, Vaduganathan M, Patel R, DeLao T, Bergeron AL, et al. Increased platelet sensitivity among individuals with aspirin resistance – Platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy. *Thrombosis and Haemostasis*. 2008;100(7):83-9.
  18. Faraday N, Becker DM, Yanek LR, Herrera-Galeano JE, Segal JB, Moy TF, et al. Preventive cardiology: Relation Between Atherosclerosis Risk Factors and Aspirin Resistance in a Primary Prevention Population. *The American Journal of Cardiology*. 2006;98:774-9.
  19. Sagdilek E, Korkmaz A, Oter S, Topal T, Ozler M, Uysal B, et al. The similarity between aspirin treatment and the lack of response to epinephrine and the frequency of aspirin resistance in healthy males. *Clinical and Applied Thrombosis/Hemostasis*. 2011;17(2):202-7.
  20. Feher G, Koltai K, Papp E, Alkonyi B, Solyom A, Kenyeres P, et al. Aspirin Resistance: Possible Roles of Cardiovascular Risk Factors, Previous Disease History, Concomitant Medications and Haemorrhological Variables. *Drugs & Aging*. 2006;23(7):559.
  21. Nidhinandana S, Changchit S. Prevalence of aspirin resistance in stroke patients in Phramongkutklao Hospital. *Journal of the Medical Association of Thailand = Chotmai het thangphaet*. 2010;93 Suppl 6:S51-4.
  22. Jastrzębska M, Chełstowski K, Siennicka A, Clark J, Wódecka A, Nowacki P. Factors influencing Multiplate whole blood Impedance Platelet Aggregometry measurements, during aspirin treatment in acute ischemic stroke: A pilot study. *Blood Coagulation and Fibrinolysis*. 2013;24(8):830-8.
  23. Petricević M, Biocina B, Konosić S, Burcar I, Sirić F, Mihaljević MZ, et al. Definition of acetylsalicylic acid resistance using whole blood impedance aggregometry in patients undergoing coronary artery surgery. *Collegium Antropologicum*. 2013;37(3):833-9.
  24. Akdogan A, Kilic L, Akman U, Dogan I, Karadag O, Bilgen SA, et al. Aspirin resistance in systemic lupus erythematosus. A pilot study. *Lupus*. 2013;22(8):835-8.

25. Kilickesmez KO, Kocas C, Abaci O, Okcun B, Gurmen T, Gorcin B. Follow-up of aspirin-resistant patients with end-stage kidney disease. *International Urology and Nephrology*. 2012;1-6.
26. Boncoraglio GB, Bodini A, Brambilla C, Corsini E, Carriero MR, Parati EA. Aspirin resistance determined with PFA-100 does not predict new thrombotic events in patients with stable ischemic cerebrovascular disease. *Clinical Neurology and Neurosurgery*. 2009;111(3):270-3.
27. Christiaens L, Ragot S, Mergy J, Allal J, Macchi L. Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study. *Blood Coagulation & Fibrinolysis : An International Journal in Haemostasis and Thrombosis*. 2008;19(3):235.
28. McCabe DJ, Harrison P, Mackie IJ, Sidhu PS, Lawrie AS, Purdy G, et al. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. *Platelets*. 2005;16(5):269.
29. Christiaens L, Macchi L, Herpin D, Coisne D, Duplantier C, Allal J, et al. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. *Thrombosis Research*. 2002;108(2-3):115.
30. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. *The American Journal of Cardiology*. 2001;88(3):230.
31. Hobikoglu GF, Norgaz T, Aksu H, Ozer O, Erturk M, Nurkalem Z, et al. High Frequency of Aspirin Resistance in Patients with Acute Coronary Syndrome. *Tohoku Journal of Experimental Medicine*. 2005;207(1):59.
32. Pamukcu B, Oflaz H, Onur I, Oncul A, Umman B, Koylan N, et al. Aspirin-resistant platelet aggregation in a cohort of patients with coronary heart disease. *Blood Coagulation & Fibrinolysis : An International Journal in Haemostasis and Thrombosis*. 2007;18(5):461.
33. Williams M, Kickler T, Vaidya D, Ng, rsquo, alla L, et al. Evaluation of platelet function in aspirin treated patients with CAD. *Journal of Thrombosis and Thrombolysis*. 2006;21(3):241.
34. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H, Grundmann K, et al. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. *Journal of neurology*. 2003;250(1):63.
35. Wong S, Ward CM, Appleberg M, Lewis DR, Wong S, Ward CM, et al. POINT OF CARE TESTING OF ASPIRIN RESISTANCE IN PATIENTS WITH VASCULAR DISEASE. *ANZ Journal of Surgery*. 2006;76(10):873.

36. Andersen K, Hurlen M, Arnesen H, Seljeflot I, Oslash, rg, et al. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. *Thrombosis Research*. 2002;108(1):37.
37. Pamukcu B, Oflaz H, Onur I, Midilli K, Yilmaz G, Yilmaz E, et al. Relationship Between the Serum sCD40L Level and Aspirin-Resistant Platelet Aggregation in Patients With Stable Coronary Artery Disease. *Circulation Journal*. 2008;72(1):61.
38. Heistein LC, Scott WA, Zellers TM, Fixler DE, Ramaciotti C, Journeycake JM, et al. Aspirin Resistance in Children with Heart Disease at Risk for Thromboembolism: Prevalence and Possible Mechanisms. *Pediatric Cardiology*. 2008;29(2):285.
39. Jussen D, Horn P, Vajkoczy P, Jussen D, Horn P, Vajkoczy P. Aspirin Resistance in Patients with Hemodynamic Cerebral Ischemia Undergoing Extracranial-Intracranial Bypass Surgery. *Cerebrovascular diseases*. 2013;35(4):355.
40. Hobikoglu GF, Norgaz T, Aksu H, Ozer O, Erturk M, Destegul E, et al. The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy. *Canadian Journal of Cardiology*. 2007;23(3):201.
41. Poulsen TS, Kristensen S, Oslash, ren R, Korsholm L, Haghfelt T, et al. Variation and importance of aspirin resistance in patients with known cardiovascular disease. *Thrombosis Research*. 2007;120(4):477.
42. Addad F, Chakroun T, Abderazek F, Ben-Farhat M, Hamdi S, Dridi Z, et al. Response variability to aspirin and one-year prediction of vascular events in patients with stable coronary artery disease. *Journal of Thrombosis and Thrombolysis*. 2010;29(1):108.
43. Aydinalp A, Atar I, Gulmez O, Atar A, Acikel S, Bozbas H, et al. The Clinical Significance of Aspirin Resistance in Patients With Chest Pain. *Clinical cardiology*. 2010;33(3):E1.
44. Coma-Canella I, Velasco A, Castano S, Coma-Canella I, Velasco A, Castano S. Prevalence of aspirin resistance measured by PFA-100. *International journal of cardiology*. 2005;101(1):71.
45. Golanski J, Chlopicki S, Golanski R, Gresner P, Iwaszkiewicz A, Watala C. Resistance to Aspirin in Patients After Coronary Artery Bypass Grafting Is Transient. *Therapeutic Drug Monitoring*. 2005;27(4):484.
46. Narvaez I, Sagastagoitia JD, Vacas M, Saez Y, Lafita M, Monica S, et al. Prevalence and biologic profile of aspirin resistance in patients with angiographically proven coronary artery disease. *Thrombosis Research*. 2007;120(5):671.
47. Fateh-Moghadam S, Plöckinger U, Cabeza N, Htun P, Reuter T, Ersel S, et al. Prevalence of aspirin resistance in patients with type 2 diabetes. *Acta Diabetol*. 2005;42(2):99-103.

48. Tasdemir E, Toptas T, Demir C, Esen R, Atmaca M, Tasdemir E, et al. Aspirin resistance in patients with type II diabetes mellitus. *Upsala journal of medical sciences*. 2014;119(1):25.
49. Golanski J, Nocu M, Rozalski M, Drygas W, Watala C. An in vitro model for the detection of reduced platelet sensitivity to acetylsalicylic acid. *Blood Coagulation & Fibrinolysis : An International Journal in Haemostasis and Thrombosis*. 2004;15(2):187.
50. Muir AR, McMullin MF, Patterson C, McKeown PP, Muir AR, McMullin MF, et al. Secondary prevention of coronary disease: Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. *Heart*. 2009;95(15):16.
51. Acikel S, Yildirim A, Aydinalp A, Bal U, Kaynar G, Ozin B, et al. The clinical importance of laboratory-defined aspirin resistance in patients presenting with non-ST elevation acute coronary syndromes. *Blood Coagulation & Fibrinolysis : An International Journal in Haemostasis and Thrombosis*. 2009;20(6):427.
52. Chakroun T, Addad F, Ben-Farhat M, Hamdi S, Gamra H, Ben-Hamda K, et al. Screening for aspirin resistance in stable coronary artery patients by three different tests. *Thrombosis Research*. 2007;121(3):413-8.
53. Cohen HW, Crandall JP, Hailpern SM, Billett HH. Aspirin resistance associated with HbA1c and obesity in diabetic patients. *Journal of Diabetes and its Complications*. 2008;22(3):224-8.
54. Kahraman G, Sahin T, Kilic T, Baytugan NZ, Agacdiken A, Ural E, et al. The frequency of aspirin resistance and its risk factors in patients with metabolic syndrome. *International journal of cardiology*. 2007;115(3):391.
55. Bozic-Mijovski M, Rakusa M, Stegnar M, Bozic-Mijovski M, Rakusa M, Stegnar M, et al. Variation in Platelet Function Testing Has a Major Influence on Detection of Aspirin Resistance in Healthy Subjects. *Pathophysiology of Haemostasis & Thrombosis*. 2008;36(2):84.
56. Takahashi S, Ushida M, Komine R, Shimizu A, Uchida T, Ishihara H, et al. Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin. *Thrombosis Research*. 2007;119(4):517.
57. Tschopp M, Reinhart WH, Tschopp M, Reinhart WH, Tschopp M, Reinhart WH, et al. Platelet aggregation under high shear conditions during and after a 28-day administration of 100 mg acetylsalicylic acid in healthy volunteers. *Clinical hemorheology and microcirculation*. 2008;38(1):45.
58. Acikel S, Yildirim A, Aydinalp A, Demirtas K, Bal U, Kaynar G, et al. Incidence of Aspirin Resistance and Its Relationship With Cardiovascular Risk Factors and Graft Function in Renal Transplant Recipients. *Transplantation Proceedings*. 2008;40(10):3485.
59. Akoglu H, Agbaht K, Piskinpasa S, Falay MY, Dede F, Ozet G, et al. High frequency of aspirin resistance in patients with nephrotic syndrome. *Nephrol Dial Transplant*. 2012;27(4):1460-6.

60. Postula M, Tarchalska-Krynska B, Filipiak K, Kosior D, Serafin A, Huczek Z, et al. Factors responsible for "aspirin resistance" - can we identify them? *Kardiologia Polska*. 2010;68(4):403-13.
61. Frelinger AL. Residual Arachidonic Acid-Induced Platelet Activation via an Adenosine Diphosphate-Dependent but Cyclooxygenase-1- and Cyclooxygenase-2-Independent Pathway: A 700-Patient Study of Aspirin Resistance. *Circulation*. 2006;113(25):2888.
62. Frelinger AL, Li Y, Linden MD, Tarnow I, Barnard MR, Fox ML, et al. Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests. *Journal of Thrombosis and Haemostasis*. 2008;6(12):2035-44.
63. Englyst NA, Horsfield G, Kwan J, Byrne CD, Englyst NA, Horsfield G, et al. Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity. *Journal of Cerebral Blood Flow and Metabolism*. 2008;28(6):1196.
64. Cao J, Liu L, Fan L, Chen T, Hu G, Hu Y, et al. The prevalence, risk factors and prognosis of aspirin resistance in elderly male patients with cardiovascular disease. *The Aging Male*. 2012;15(3):140.
65. Tantry US, Bliden KP, Gurbel PA, Tantry US, Bliden KP, Gurbel PA. Overestimation of Platelet Aspirin Resistance Detection by Thrombelastograph Platelet Mapping and Validation by Conventional Aggregometry Using Arachidonic Acid Stimulation. *Journal of the American College of Cardiology*. 2005;46(9):1705.
66. Thomson VS, John B, George P, Joseph G, Jose J, Thomson VS, et al. Aspirin resistance in Indian patients with coronary artery disease and cardiovascular events. *Journal of postgraduate medicine*. 2009;55(4):252.
67. Goncalves LH, Dusse LMSA, Fernandes AP, Gomes KB, oacute, ter MO, et al. Urinary 11-dehydro thromboxane B2levels in type 2 diabetic patients before and during aspirin intake. *Clinica chimica acta*. 2011;412(15-16):1366.
68. Bordeaux BC, Qayyum R, Yanek LR, Vaidya D, Becker LC, Faraday N, et al. Effect of Obesity on Platelet Reactivity and Response to Low-Dose Aspirin. *Preventive cardiology*. 2010;13(2):56.
69. Eskandarian R, Darabian M, Heshmatnia J, Ghorbani R. Acetyl salicylic acid resistance in patients with chronic stable angina and the correlation with coronary risk factors. *Saudi Medical Journal*. 2012;33(1):39-43.
70. Wojtowicz A, Undas A, Huras H, Musial J, Rytlewski K, Reron A, et al. Aspirin resistance may be associated with adverse pregnancy outcomes. *Neuroendocrinology Letters*. 2011;32(3):334-9.
71. Chen W-H, Cheng X, Lee P-Y, Ng W, Kwok JY-Y, Tse H-F, et al. Aspirin Resistance and Adverse Clinical Events in Patients with Coronary Artery Disease. *American Journal of Medicine*. 2007;120(7):631.

72. Can MM, Tanbo, a, brahim H, uuml, rky, et al. The risk of false results in the assessment of platelet function in the absence of antiplatelet medication: Comparison of the PFA-100, multiplate electrical impedance aggregometry and verify now assays. *Thrombosis Research*. 2010;125(4):e132.
73. Mirkhel A, Peyster E, Sundeen J, Greene L, Michelson AD, Hasan A, et al. Frequency of Aspirin Resistance in a Community Hospital. *The American Journal of Cardiology*. 2006;98(5):577.
74. Dyszkiewicz-Korpanty AM, Kim A, Burner JD, Frenkel EP, Sarode R, Dyszkiewicz-Korpanty AM, et al. Comparison of a rapid platelet function assay &ndash; Verify Now&trade; Aspirin &ndash; with whole blood impedance aggregometry for the detection of aspirin resistance. *Thrombosis Research*. 2007;120(4):485.
75. Kim KE, Woo KS, Goh RY, Quan ML, Cha KS, Kim MH, et al. Comparison of laboratory detection methods of aspirin resistance in coronary artery disease patients. *International Journal of Laboratory Hematology*. 2010;32(1p2):50.
76. Lee PY, Chen WH, Ng W, Cheng X, Kwok JYY, Tse HF, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. *American Journal of Medicine*. 2005;118(7):723.
77. Yassine HN, Davis-Gorman G, Stump CS, Thomson SS, Peterson J, McDonagh PF, et al. Clinical determinants of aspirin resistance in diabetes. *Diabetes research and clinical practice*. 2010;90(1):e19.
78. Geara AS, Azzi N, Bassil C, El-Sayegh S, Geara A, Azzi N, et al. Aspirin resistance in hemodialysis patients. *International Urology and Nephrology*. 2012;44(1):323.
79. Dawson J, Quinn T, Lees KR, Walters MR, Dawson J, Quinn T, et al. Microembolic Signals and Aspirin Resistance in Patients with Carotid Stenosis : Microembolic Signals and Aspirin Resistance. *Cardiovascular Therapeutics*. 2012;30(4):234.
80. Seok JI, Joo IS, Yoon JH, Choi YJ, Lee PH, Huh K, et al. Can aspirin resistance be clinically predicted in stroke patients? *Clinical neurology and neurosurgery*. 2008;110(2):110.
81. Dawson J, Quinn T, Rafferty M, Higgins P, Ray G, Lees KR, et al. Aspirin Resistance and Compliance with Therapy. *Cardiovascular Therapeutics*. 2011;29(5):301-7.
82. Kim H, Lee H, Han K, Jeon H. Prevalence and risk factors for aspirin and clopidogrel resistance in patients with coronary artery disease or ischemic cerebrovascular disease. *Annals of Clinical and Laboratory Science*. 2009;39(3):289.
83. Vaturi M, Vaduganathan M, Bental T, Solodky A, Kornowski R, Lev E. Relation of Aspirin Response to Age in Patients With Stable Coronary Artery Disease. *The American Journal of Cardiology*. 2013;112(2):212-6.